Pfizer Inc. (PFE)
Top Stock Movers Now: Spotify, Pfizer, CoreWeave, Lamb Weston, and More
Major U.S. equities indexes edged lower Tuesday afternoon, as a potential government shutdown loomed. The Dow, S&P 500, and Nasdaq were all slightly lower.
US drugmakers rise after Trump announces Pfizer price cuts, promises more deals
Shares of Pfizer rose about 5% after U.S. President Donald Trump said on Tuesday the drugmaker will cut the price on all of its prescription drugs sold to the Medicaid insurance program and will introduce all new prescription drugs at a "most favored nation" price.
Pfizer first to offer 'major discounts' to US customers via govt website, says Trump
Pfizer Inc (NYSE:PFE, ETR:PFE) shares jumped 3.5% after Donald Trump said the drugmaker would be the first company offering lower prices on its prescription drugs. Under a new agreement with the White House, the company will offer "major discounts" under the "most favoured nation" drug pricing order established earlier this year.
Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.
Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.
Trump, Pfizer to announce agreement to lower drug prices
President Donald Trump will announce an agreement with Pfizer to voluntarily sell its medications at lower prices, as his administration pushes to link U.S. drug prices to the cheaper prices paid abroad. In this article PFE
White House to Announce ‘TrumpRx' Drug-Buying Website, and Deal With Pfizer
President Trump is expected to unveil the measures with Pfizer's CEO on Tuesday
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer is Locking in New Growth Through a New Acquisition
In the United States' healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug manufacturing and distribution businesses are all the hype for this new growth wave taking over the industry.
Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?
Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).
Pfizer acquires Metsera in $7.3B deal to boost obesity drug pipeline
Pfizer Inc (NYSE:PFE, ETR:PFE) on Monday announced that it will acquire Metsera, Inc (NASDAQ: MTSR), a weight-loss drug developer, in a deal valued at up to $7.3 billion, or $47.50 per share in cash. Metsera is also eligible to receive an additional $22.50 per share contingent on the achievement of certain performance milestones.
Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal
Metsera's shareholders could see significant bonuses if certain milestones are reached.
Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports
Pfizer is closing in on a potential $7.3 billion takeover of anti-obesity drug developer Metsera , the Financial Times reported on Sunday, citing unidentified sources.
